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Abstract
Mesenchymal Stromal cells (MSCs) have a potential role in cell-based therapies. Foetal
bovine serum (FBS) is used to supplement the basal cell culture medium but presents sev-
eral disadvantages and risks. Other alternatives have been studied, including human umbili-
cal cord blood plasma (hUCBP), aiming at the development of xeno-free culturing protocols.
A comparative characterization of multicomponent metabolic composition of hUCBP and
commercial FBS based on Nuclear Magnetic Resonance (NMR) spectroscopy and multivar-
iate statistical analysis was performed. The analysis of 1H-NMR spectra revealed both simi-
larities and differences between the two proposed supplements. Similar metabolites (amino
acids, glucose, lipids and nucleotides) were found in the hUCBP and FBS NMR spectra.
The results show that the major difference between the metabolic profiles of the two pro-
posed supplements are due to the significantly higher levels of glucose and lower levels of
lactate, glutamate, alanine and branched chain amino acids in hUCBP. Similar or slightly dif-
ferent levels of important proteinogenic amino acids, as well as of nucleotides, lipids were
found in the hUCBP and FBS. In order to validate it’s suitability for cell culture, umbilical
cord-MSCs (UC-MSCs) and dental pulp stem cells (DPSCs) were expanded using hUCBP.
In both hMSCs, in vitro culture with hUCBP supplementation presented similar to improved
metabolic performances when compared to FBS. The two cell types tested expressed differ-
ent optimum hUCBP percentage content. For DPSCs, the optimum hUCBP content was 6%
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and for UC-MSCs, 4%. Cultured hMSCs displayed no changes in senescence indicators, as
well as maintained characteristic surface marker’s expression. FBS substitution was associ-
ated with an increase in early apoptosis events, in a dose dependent manner, as well as to
slight up- and down-regulation of targeted gene’s expression. Tri-lineage differentiation
capacity was also influenced by the substitution of FBS by hUCBP.
1. Introduction
Mesenchymal Stem / Stromal Cells are gaining ground as a source of innovative advanced
therapeutic strategies for a number of diseases, with hundreds of ongoing or recruiting trials
involving application of Human Mesenchymal Stromal Cells (hMSCs) (www.clinicaltrial.gov;
database accessed on January 2018). As such, the scientific community has focused on devel-
oping and optimising protocols for their isolation, expansion, and cryopreservation aiming at
their effective application in state of the art therapeutic approaches to relevant clinical situa-
tions. MSCs can be isolated from many tissue sources, such as the bone marrow, peripheral
blood, dental pulp, umbilical cord, and amniotic fluid [1]. Human MSCs characteristics have
been defined by the Mesenchymal and Tissue Stem Cell Committee of the International Soci-
ety for Cellular Therapy [2] as being plastic-adherent when maintained in standard culture
conditions, expressing cluster of differentiation (CD) 105, CD73 and CD90, and lacking
expression of CD45, CD34, CD14 or CD11b, CD79α or CD19 and HLA-DR surface mole-
cules. Finally, the hMSCs are able to differentiate into osteoblasts, adipocytes and chondro-
blasts in vitro, in the presence of adequate differentiation media [3].
The umbilical cord tissue or matrix (Wharton jelly–UCT) is an important source of MSCs,
baring advantages over other sources for being non-invasively collected (previously considered
as medical waste). Also, increasing numbers of high quality cryopreserved samples worldwide,
in private and public cryopreservation banks, and the ready availability for therapeutic usage
[4–12] adds a further advantage. Dental derived stem cells are other population with increasing
relevance, mostly due to the increasing availability of cryopreservation options, for autologous
and allogeneic applications, in both infants and adult individuals.
According to the European Medicines Agency (EMA) and European Commission regula-
tion [EC 1394/2007 of the European Commission], hMSCs are considered as medicinal prod-
ucts and must be produced in compliance with good manufacturing practices (GMP) [13]. For
that purpose, stem cells from either source must be cultured on large scale, and isolated, pro-
cessed and cryopreserved according to GMP conditions. This implies the usage of xeno-free
medium and reagents of clinical grade for the cell culture, for quality assurance and control,
and long term rastreability of the samples [8, 14, 15].
Currently available hMSCs expansion protocols use foetal bovine serum (FBS) and other
animal sera for culture media supplementation, providing vital nutrients and growth factors.
These also act as a pH buffering agent, and provide protection against cytotoxic components,
playing a crucial role in hMSCs survival. Nonetheless, there are several concerns on the use of
FBS for clinical applications, due to the potential immunogenicity of FBS cultured cells and of
xenogeneic proteins present in the cell culture, capable of inducing anaphylactic or arthus-like
immune reactions, which have been reported. Notwithstanding this, FBS-cultured hMSCs
have been approved by the US Food and Drug Administration (FDA) for medical applications
[16, 17]. Complications of using animal sera for in vitro cell culture also include high batch-to-
batch variability, unexpected cell growth characteristics, cytotoxicity of uncharacterized factors
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in the serum, and the risk of possible contamination with virus, prions, bacteria, nanobacteria,
mycoplasma, yeast, fungi, and endotoxins [1, 7, 8, 18–21]. The use of animal sera also implies
the sacrifice of a huge number of young animals for blood collection, entailing severe eco-
nomic, ethical and scientific issues on animal welfare [8].
These issues reinforce the intensive search for new alternatives to animal sera to better com-
ply with GMP and FDA regulations (EMEA CPMP/BWP/1793/02; 2003; EMEA/410/01 rev. 2;
2004) [22, 23]. The substituent cell culture medium supplement must match the animal sera
characteristics crucial for ex vivo cell culture, while maintaining a fair cost, being suitable for
safety and quality control, and readily/easily available. A variety of human blood products
have been already considered as animal sera substituents [15, 24–26]. Amongst them, human
umbilical cord blood serum or plasma (hUCBS or hUCBP, respectively), due to its rich soluble
growth factors’ content. These soluble factors support the growth, proliferation, and differenti-
ation of hMSCs and HSCs [15, 26, 27], with potential pre-clinical and clinical applications [6–
8, 14, 28]. The implementation of hUCBS or hUCBP could solve important economic, ethical
and scientific issues associated with FBS supplementation in cell-based therapies development.
Moreover, the hUCBS and hUCBP are attractive alternatives to FBS due to the worldwide
increase number of cryopreserved UCB units in Public and Private Cord Blood Banks, follow-
ing high quality standards imposed by the international and national authorities [4–9, 29].
The successful employment of hUCBP can result in the preparation of fully autologous cel-
lular therapies, for patients with cryopreserved serum/plasma and cells or tissue. Alternatively,
once the regulatory requisites are established, it can be envisioned for the preparation of allo-
geneic cellular therapies. This would bring increased benefits for a larger number of patients,
and turning cellular therapies promptly available, allowing medical action in optimal ‘windows
of therapeutic opportunity’ for numerous diseases. Additionally, it would contribute to the
broadening of possible beneficiaries for such therapies, including people that might have not
had the chance to preserve autologous samples, and that may be in need of these advanced
therapeutic strategies (for example, suffering from age-related of degenerative diseases).
In a previous study, we have identified specific components and factors (proliferative and
anti-apoptotic growth factors, immunomodulatory and immunosuppressive cytokines and
chemokines) in hUCBP that could have promoting effects on hMSCs in vitro expansion. The
results strongly suggest that hUCBP might be an alternative for the FBS supplemented culture
medium used in hMSCs in vitro isolation, expansion and cryopreservation [4, 8]. This assump-
tion converges with the recently published results on the effect of haemoderived supplements
on the hMSCs growth rate, viability and differentiation properties [15, 26, 30–33]. For this pur-
pose, a detailed analysis of the hUCBP components is crucial to validate this human haemo-
derivate by-product as a supplement for ex vivo expansion and processing of hMSCs for
clinical applications.
Metabolomics is an important and well-established analytical approach for the comprehen-
sive and systematic determination of metabolite levels in biological samples. Nuclear magnetic
resonance (NMR) spectroscopy is one of the main tools for metabolic profiling, identification
and quantification of known and unknown metabolites in bio-fluids, tissues and cells. [34–36].
All metabolomics studies including NMR-metabolomics, result in a large number of complex
multivariate data sets that require chemometric and bio-informatics methods for accurate data
interpretation, visualization and analysis [37, 38]. Data-reduction and pattern recognition
techniques such as principal component analysis (PCA) allow for analysis, interpretation and
classification of the large number of complex NMR spectroscopic data usually acquired for
metabolic profiling of biological samples [34–36, 39, 40].
The first part of this study aims at the characterization of the metabolite composition of
hUCBP, to address its capacity as a culture medium supplement and FBS substituent to
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support xeno-free in vitro proliferation of hMSCs. The second part of the study aimed at
the validation of hUCBP substitution for the expansion of umbilical cord (UC-MSCs) and
dental pulp- derived mesenchymal stem cells (DPSCs), and its effects on cell viability and
senescence, surface marker- and gene expression, as well as on their tri-lineage differentiation
capacity.
2. Material and methods
The hUCB samples included in the present study were processed and cryopreserved by
Biosckin, Molecular and Cell Therapies S.A. (Maia, Portugal), which is an authorized Portu-
guese Private Cord Blood Bank for UCB processing and cryopreservation by the Direção-
Geral de Saúde (DGS), and certified for ISO9001 and for NP4457 (Authorization from DGS in
attachment). The hUCB was collected from healthy donors that signed a contract with
Biosckin, Molecular and Cell Therapies S.A. for processing and cryopreserved the buffy coat of
the collected umbilical cord blood where the hematopoietic stem cells are included. On the
other hand, the hUCB plasma is not cryopreserved and it is a by-product which is not cryopre-
served and it is usually destroyed. The present experimental work used those hUCB plasmas
and it should be emphasized that the donors that have this contract with Biosckin, Molecular
and Cell Therapies S.A. authorize the use of these by-products for research. Patient records
used in our retrospective study were fully anonymized before the authors accessed the data for
the present study and the ethics committee waived the requirement for informed consent.
Also, there is a scientific protocol / contract between the University of Porto and the Biosckin,
Molecular and Cell Therapies S.A., which includes I&D projects, PhD and master supervision
of students, among other training and teaching activities. For that reason, it was not necessary
to submit this study to approval of the ethical commission.
2.1. Study design
In the first part of the study, appropriate 1D and 2D NMR techniques have been used to iden-
tify metabolites in the hUCBP (a total number of 13 samples collected from healthy donors)
and two commercial FBS products (FBS_I and FBS_II), and to define their relative quantitative
distribution. Principal component analysis has been used to interpret and classify the NMR
spectral data and to evaluate the main factors contributing to the discrimination between these
two groups of samples. Prior to NMR analysis, a complete characterization of the hUCB sam-
ples was performed (haematology for total nucleated cells (TNC) and white blood cells (WBC)
count, flow cytometry for CD45+ / CD34+ cell counts, and cell viability), accompanied by pre-
birth and immediate after-birth maternal screening for relevant transmittable pathogens,
including Cytomegalovirus, Venereal disease/ Syphilis, Hepatitis B and C, HIV-I and II, Toxo-
plasmosis (and Human T-Cell Lymphotropic Virus Types I and II (HTLV-I/-II), if relevant).
Microbiological analysis was performed to hUCB units after volume reduction using an auto-
mated blood culture system for aerobic and anaerobic microorganisms and fungi.
In the second part of the study, the capacity of hUCBP to sustain both hMSCs expansion
was assessed with PrestoBlue1 viability assay at different time points [24h, 72h, 120h, 168h,
216h], using umbilical cord-MSCs (UC-MSCs) and dental pulp stem cells (DPSCs). Crescent
concentrations of hUCBP were added as a supplement of the basal culture medium [2%, 4%,
6%, 8%], and compared with FBS_II at 10%, generally used standard culturing protocols. The
effects of the supplement substitution on hMSCs cultures were assessed regarding senescence
and apoptosis events, hMSCs’ phenotypical identity/ surface marker and gene expression, as
well as tri-lineage differentiation capacity.
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2.2. Ethics and regulation
The hUCB included in the present study were processed and cryopreserved by Biosckin,
Molecular and cell Therapies S.A. (Maia, Portugal), an authorized Portuguese Private Cord
Blood Bank for UCB processing and cryopreservation by the Direcção-Geral de Saúde (DGS),
and certified for ISO9001 and for NP4457. The hUCB was collected from healthy donors,
according to Netcord guidelines and following Portuguese laws N˚ 12/2009 and N˚ 1/2015
(Diário da República, lei 12/2009 de 26 de Março de 2009 and Diário da República, lei 1/2015
de 8 de Janeiro de 2015), with written informed consents according to Directive 2004/23/EC,
which sets the standards of quality and safety for the donation, procurement, testing, process-
ing, preservation, storage and distribution of human tissues and cells.
2.3. Preparation of umbilical cord plasma
Thirteen samples of hUCBP collected from different healthy donors were used for 1H-NMR
analysis (N = 13). The hUCBP samples were analysed by haematology auto-analyser, flow
cytometry and for microbiological contamination for aerobic and anaerobic microorganisms
and fungi. A pool from 12 out of 13 of these hUCBP (N = 12) was used for the in vitro valida-
tion with UC-MSCs and DPSCs viability assessment.
2.4. Donors selection and umbilical cord blood (UCB) collection
Maternal and neonatal pairs were evaluated during the antenatal period in the maternity
wards at different hospitals collaborating with the Umbilical Cord Blood Private Bank of
Biosckin, Molecular and Cell Therapies, S.A. (Maia, Portugal). Donors signed informed con-
sent before delivery and were clinically evaluated according to Portuguese law (Diário da
República, lei N˚ 12/2009 de 26 de Março de 2009 and lei N˚ 1/2015 de 8 de Janeiro de 2015).
Human UCB was collected from the umbilical vein by gravity into a 150 ml volume simple bag
(reference #1385.13, Suru, Portugal) containing 21 ml of citrate-phosphate-dextrose (CPD).
The hUCB was stored at 4˚C ± 2˚C until processing for cryopreservation. Human UCB sam-
ples were transported to the Biosckin, Molecular and Cell Therapies S.A. laboratory at refriger-
ated temperatures ranging between 4˚C and 22˚C, within 72 hours of collection. The
collection method was the same for all the units included in this study.
2.5. Volume reduction with the AXP automated system
The AXP system1 (Thermogenesis) was used to achieve the separation of a concentrated
mononuclear cell (MNC) fraction of uniform volume. During the two-step centrifugation,
whole blood is separated into three layers that are delivered into a red blood cells (RBC) bag
and a freezing bag. Plasma remains in the processing bag which is also the plasma bag. The
programmed final volume in the cryopreservation bag was 21 ml. Samples of the hUCB were
taken by sampling pillows integrated within the kit for hematology auto-analyzer and flow
cytometry analysis [8, 41–43].
2.6. Haematology auto-analyzer, flow cytometry and microbiological
analysis of the UCB
Maternal screening for Cytomegalovirus, Venereal disease/ Syphilis, Hepatitis B and C, HIV-I
and II, Toxoplasmosis (and Human T-Cell Lymphotropic Virus Types I and II (HTLV-I/-II),
if relevant) was mandatory for sample acceptance for processing. All cryopreserved samples
were negative to the screened agents. Microbiological analysis was performed after volume
reduction and before cryopreservation (samples are maintained in quarantine until final
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results are disclosed) using an automated blood culture system (BacT/ALERT1, BioMérieux)
at 35˚C for 14 days, and included microbiologic analysis for aerobic and anaerobic microor-
ganisms and fungi. For the UCB units that presented microbial contamination, the microor-
ganism was identified and was performed the antibiogram for identification of the antibiotic
sensitivity of the identified microorganisms [8].
Total nucleated cells (TNC) and the number of white blood cells (WBC) were counted with
a hematology auto-analyzer (Ac T diff2™, Beckman Coulter, Inc.) before and after the AXP vol-
ume reduction procedure. These counts were not corrected for nucleated RBC. The CD34+
cell number and viability were quantified by flow cytometry (BD FACSCalibur™ 3 CA Becton
Dickinson, BD Biosciences), the software for acquisition and analysis were BD CellQuest™ and
BDCellQuest Pro Templates, respectively. The clusters of differentiation used to enumerate
the total number of CD34+ cells and the total number of leucocytes (CD45+), the 7-Amino-
Actinomycin D (7AAD) nucleic acid dye was used for viability measure (BD Stem Cell Enu-
meration kit, Becton Dickinson, BD Biosciences), according to the manufacturer’s protocol.
The BD Stem Cell Enumeration simultaneously enumerates the total viable dual-positive
(CD45+/CD34+) hematopoietic stem cells in absolute counts of CD34+ cells per μL and the
percentage (%) of viable leucocytes (CD45+) that are CD34+ [8].
2.7. FBS commercial samples
The two FBS formulations commercially available as a supplement for hMSCs culture rou-
tinely used by our research group for in vitro isolation and expansion were tested. The FBS_I
was obtained from GIBCO (Gibco1 Invitrogen, EU Approved FBS, Origin South America,
Heat Inactivated, and reference #10500–064). The FBS_II was obtained from BI, Biological
Industries (BI LTD, Certified FBS, reference #04-400-1A), and is classified for human MSCs,
0.1 μm membrane filtered, tested for mycoplasma, and virus screened. This FBS_II is heat
inactivated, sterile-filtered, and according to the manufacturer information, presents hemoglo-
bin in a concentration�25 mg/dl, and�10 EU/ml endotoxin, and it was used for the in vitro
validation. For both formulations, 3 different samples obtained from a different lot were tested
in the 1H-NMR experiments (N = 3).
2.8. Part I: Supplements metabolomic characterization
2.8.1. NMR spectroscopy. A 600 μl aliquot of each sample was transferred into 5 mm
NMR tubes and mixed with 50 μl deuterium oxide (D2O) containing 0.05mM sodium tri-
methylsilyl-[2,2,3,3-d4]-propionate (TSP) as an internal reference. The NMR experiments
were recorded at 300K on a Bruker Avance III 600 HD spectrometer, equipped with Cryo-
Probe Prodigy. All 1H NMR spectra were acquired with water suppression using a 1D NOESY
(noesygppr1d) and a Carr-Purcell-Meiboom-Gill (CPMG, cpmgpr1d) pulse sequences [44,
45]. The 1D NOESY spectra were collected using 5s relaxation delay and mixing time of 0.01s.
The CPMG experiments (cpmgpr1d) were acquired with relaxation delay 4s, during which the
water resonance signal was selectively irradiated. The echo time was optimized for each sample
and was between 0.3 and 0.8 ms, and a loop for T2 filter of 20 was used. For all 1H-NMR spec-
tra 128 or 256 transients of a spectral width of 10000 Hz were collected into 32 K time domain
points. The spectra were processed with the Bruker Topspin software package (version 3.2).
The time domain data were multiplied by an exponential function with line-broadening factor
of 0.3 Hz and zero-filled to 64 k prior to Fourier transformation. Two dimensional (2D)
1H/1H COSY and TOCSY spectra were recorded in phase sensitive mode and with water sup-
pression; a relaxation delay of 2s, 16 or 32 scans, a total 2K data points in F2 and 256 or 512
data points in F1 over a spectral width of 10000 Hz. 2D 1H/13C heteronuclear single quantum
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coherence (HSQC) experiments were carried out with a spectral width of 10000 Hz for 1H and
27000 Hz for 13C, relaxation delay 1.5 s, Fourier transform (FT) size 2Kx1K. The quantitative
distribution of NMR-detectible metabolites in hUCBP and FBS (FBS_I and FBS_II) analysed
samples was determined from the integral intensity of characteristic signals in 1H-NMR spec-
tra of the samples referenced to the total integral intensity of the signals in the spectra, consid-
ering the number of the contributing nuclei for that particular resonance signal.
2.8.2. Multivariate statistical analysis of NMR spectroscopy data. In the present study,
the integral intensities over small chemical shift regions (bins) of size 0.01 ppm over the spec-
tral region between 0.50 and 9.00 ppm were used as descriptors for interpretation and statisti-
cal analysis of the NMR data. Data was normalized by the total sum of the integral intensities
in the spectral region of interest. In all studies the water and citric acid spectral regions were
excluded. Additionally, a separate NMR-data set was prepared with the regions containing
sugars and lactate resonance signals excluded. The Principal Component Analysis (PCA), an
unsupervised pattern recognition approach, was applied to examine the intrinsic variation in
the data set and compare the metabolic profiles of the 13 hUCBP samples and 2 commercial
formulations of FBS (FBS_I and FBS_II) [46]. PCA determines the independent sources of var-
iance across a set of spectra and ranks these Principal Components (PCs) in order of their con-
tribution to the overall variance. PCA facilitates the identification of the sources of variation
relevant to systematic changes in a number of key features in the NMR spectra. Based on the
singular values decomposition (SVD) technique, Principal Components (PCs) are extracted
from the initial NMR data matrix. Each PC is orthogonal (uncorrelated) with all other PCs.
The PCs are ordered based on their information content, with the first few PCs containing the
largest part of the variance of the data set. Two dimensional PC maps (PC1 vs. PC2) were used
as a convenient way to visualize inherent data clusters and outliers, and make conclusions on
the degree of correlation between the hUCBP and both FBS samples. If there are systematic
metabolic differences between samples, similar samples may cluster together in the scores plot,
and classification of the samples may be possible. Further, PC loading plots (ppm vs. PC1 or
PC2) were used to reveal the main metabolites and the associated spectral regions responsible
for the NMR data variability. The loading plots define the contribution of variables, i.e. the
metabolite content for the divergence or clustering between the samples [34–36].
2.9. Part II: In vitro validation
2.9.1. Cell viability assessment. Cell culture and maintenance: UC-MSCs and DPSCs
were thawed and in vitro expanded using standard protocols previously reported by our
research group [4–12, 29, 47–49]. UC-MSCs and DPSCs were maintained at 37˚C and 95%
humidified atmosphere with 5% CO2 environment. UC-MSCs were obtained from PromoCell,
Cat. C-12971; Lot No. 1112304.2) and DPSCs from AllCells, LLC (Cat. DP0037F, Lot No.
DPSC090411-01). MSCs’ batches identity was confirmed through flow cytometry analysis.
Passage 5–7 cultures were utilized in the presented assays in both cell populations. Both popu-
lations were initially maintained in αMEM, with GlutaMAX™, without nucleosides (Gibco,
reference #32561029) supplemented with 10% (v/v) FBS, 100 IU/ml penicillin, 0.1 mg/ml
streptomycin (Gibco, reference #15140122), 2.05 μg/ml amphotericin B (Gibco, reference
#15290026) and 10 mM HEPES Buffer solution (Gibco, 15630122). For the in vitro viability
studies, the FBS_II was selected for culture medium supplementation of both hMSCs types
under study.
PrestoBlue Cell Viability Protocol: The PrestoBlue (Thermo Fisher Scientific, Molecular
Probes) assay is a commercially available, ready-to-use, water-soluble preparation. Cells were
seeded in 24 well plate at 4x103 cells/well. The cells were left adhering in complete culture
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medium, overnight. After this period, culture media was replaced by test media [αMEM with
GlutaMAX, without nucleosides supplemented with either 2%, 4%, 6%, or 8% of hUCBP pool
or 10% FBS (v/v), 100 IU/mL penicillin, 0.1 mg/ml streptomycin, 2.05 μg/ml amphotericin B
and 10 mM HEPES buffer solution]. Previous experimental set ups revealed jellification of the
hUCBP supplemented medium, despite of its collection and transportation in CPD containing
collection bags. Hence, heparin (Heparin Sodium, 5.000 IU/ml, BBraun1) was added to the
hUCBP supplemented medium formulations, at 2 UI/ml. Preliminary assays presented no sig-
nificant effect of heparin addition on standard culture conditions, using 10% FBS supple-
mented αMEM (data not shown).
At every time point [24 hours (1 day), 72 hours (3 days), 120 hours (5 days), 168 hours (7
days), and 216 hours (9 days)], the culture media was removed and fresh adequate culture
media was added to each well, with 10% (v/v) of 10x PrestoBlue cell viability reagent (Thermo
Fisher Scientific, Molecular Probes, Invitrogen, reference #A13262), and UC-MSCs and
DPSCs were incubated for 1 hour at 37˚C, 5% CO2. Changes in cell viability were detected by
absorbance spectroscopy of cell culture supernatant, and absorbance was read at 570nm and
595 nm in a Thermo Scientific Multiskan FC plate reader. Absorbance readings were normal-
ized and data corrected to unseeded control wells’ readings. At each time point, sample wells
were harvested using Trypsin-EDTA and triplicate cell counts were performed with Trypan
Blue exclusion dye assay (15250061, Gibco), using an automated counter (CountessTM II FL
Automated Cell Counter, Invitrogen).
2.9.2. Senescence and apoptosis. To assess for signs of senescence in the cellular popula-
tions, β-Galactosidase activity was assayed. Cells were plated in 96-well plates, as described for
the growth dynamics assessment, maintaining the assigned hUCBP or FBS supplemented
media. At 3, 5 and 7 days [72, 120 and 168 hours], culture media was removed, and cells were
washed once with DPBS and incubated with β-Galactosidase Assay Reagent (75705, Thermo
Fisher Scientific), for 30 minutes at 37˚C. Absorbance was read at 405 nm. UC-MSCs and
DPSCs cultured in either hUCBP or FBS supplemented media were further assessed for apo-
ptosis events, through the detection of Annexin V and Propidium Iodine (PI) staining
(BMS500FI, eBioscience). For such, cells cultured for 5 days in each condition were harvested
using Trypsin-EDTA, counted and resuspended in provided Binding Buffer. Cells were incu-
bated with Annexin V-FITC and PI, as per manufacturer’s protocol, and FACS analysis was
performed using a Coulter Epics XL Flow Cytometer (Beckman Coulter Inc., Miami, FL,
USA). Flow cytometry data was processed using FlowJo Engine X10.4 (v3.05478, LLC).
2.9.3. MSCs’ Phenotype identity. The surface marker profiles of UC-MSCs and DPSCs
cultured in either hUCBP or FBS supplemented media were assessed though Flow Cytometry.
MSCs populations were cultured for 5 days, as described previously and harvested using Accu-
taseTM Cell detachment solution (561527, BD Biosciences), counted and resuspended in Stain
Buffer (554676, BD Biosciences). Cells were incubated with anti-positive (CD90, CD105,
CD44) and negative marker (CD34, CD11b, CD19, CD45, MHC class II) antibodies and
assayed as per manufacturer’s instructions (Human MSC Analysis Kit, 562245, BD Biosci-
ences), using a BD FACSCalibur 3 CA Becton Dickinson, BD Biosciences. Flow cytometry
data was processed using FlowJo Engine X10.4 (v3.05478, LLC).
2.9.4. Gene expression. Reverse transcriptase Polymerase chain reaction (RT-PCR) and
qPCR was performed targeting housekeeping and MSCs’ related gene sequences listed in
Table 1.
MSCs populations cultured in the described media were harvested using Trypsin-EDTA, as
previously described, and pellets of 106 cells of each group were used for total RNA extraction,
using the AurumTM Total RNA Mini kit (732–6820, Bio Rad). Briefly, cell pellets were lysed,
DNA was removed with DNase I enzyme and obtained RNA was eluted. Total RNA was
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quantified using a nanophotometer readings at 260 and 280 nm (NanoPhotometerTM Pearl,
Implen GmbH). Once RNA concentrations were tuned between samples, cDNA was synthe-
sized from the purified RNA using the iScript Reverse Transcription kit (170–8891, Bio Rad)
and T100 Terma Cyclar Thermocycler (Bio Rad), as per manufacturer’s instructions. Quanti-
tative PCR (qPCR) was performed in a CFX96 TouchTM (BioRad) apparatus using the
iTAQTM SYBR1 Green Supermix (172–5120, BioRad) and custom PCR plates encompassing
duplicates of targeted human genes and negative control (Table 1). Recommended PrimePCR
cycling protocol was employed: 95˚C for 2 minutes (activation), 40 cycles comprising 95˚C for
5 seconds (denaturation) -60˚C for 30 seconds (annealing), and 65 to 95˚C (0.5˚C increments),
5 secs/step (melt curve). The number of cycle threshold for each well was recorded. Data was
processed using BioRad CFX1Manager Software 3.1 (Bio Rad Laboratories). Fold differences
were calculated using the standard ΔΔCq method with GAPDH and β-actin as housekeeping
genes. The reference gene on the hUCBP supplemented samples was calculated relative to cali-
brator sample (FBS10%) (fold change between two Cq values) through the equation: Relative
quantification (RQ) = 2ΔΔCt
2.9.5 Multilineage differentiation. Osteogenic and Adipogenic differentiation proto-
cols—MSCs were seeded onto 24-well plates (8.000 viable cells/cm2), and cultured with either
FBS or hUCBP supplemented media until 70–80% confluence was reached (after 3 days). At
this point, cells were transitioned to specific differentiation media: Adipogenesis (StemPro
Adipogenesis Differentiation kit, A10070-01, Gibco), following manufacturer’s instructions,
or formulated Osteogenesis medium, composed of expansion media further supplemented
with 5nM Dexamethasone (D8893 –Sigma Aldrich1), 250 μM de ascorbic acid-2- phosphate
(AsA2-P, A4403, Sigma Aldrich)) e 10mM β-glycerphoshate (β-GP, G9422, Sigma Aldrich).
Xeno-free Osteogenic formulations were prepared using 4%, 6% or 8% hUCBP supplementa-
tion [50]. Control wells were maintained in culture media absent osteogenic supplements.
Media were changed every 3 days, for 21 days, for Adipogenesis and Osteogenesis, respectively.
After 14 days, cells under Adipogenic differentiation were stained with Oil Red O, for lipid
droplets detection and semi-quantification. Alizarin Red S Assay was employed to asses for
Osteogenic differentiation after 21 days; Oil Red O (Qualitative and Semi-Quantitative):
Cells were fixated with 4% formaldehyde (3.7–4% buffered to pH7, 252931.1315, Panreac
AppliChem) and incubated with Oil Red O (O0625, Sigma-Aldrich) working solution for 10–
Table 1. Primer sequence information for qRT-PCR custom plate array.
Gene Length (bp) Bio Rad Assay ID
MSCs targets
CD34 99 qHsaCID0007456
CD90/ THY1 120 qHsaCED0036661
CD73/ NT5E 117 qHsaCID0036556
CD105/ ENG 124 qHsaCID0010800
CD166/ ALCAM 173 qHsaCID0037887
CD117/ c-kit 63 qHsaCID0008692
SOX2 98 qHsaCED0036871
OCT3-4/ POU5F1 100 qHsaCED0038334
MHC class I/ HLA-A 115 qHsaCED0037388
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20 minutes at room temperature. Oil Red O was discarded and excess dye removed. Differenti-
ated cells were observed under inverted microscope (Axiovert 40 CFL, Zeiss). For semi-quanti-
fication, Oil Red O stain was eluted through the addition of 100% isopropanol (59300, Merck
Milipore1), and absorbance was read at 570 nm; Alizarin Red S (Qualitative and Semi-
Quantitative): ARS Assay was used to qualitatively and semi-quantitatively determine Osteo-
genic differentiation of hMSCs, as described in [50]. Cells were fixed with 4% formaldehyde
and stained with 40 mM ARS (2003999, Milipore) and incubated for 30 min with gentle shak-
ing. Following incubation, unbound dye was removed and wells were washed with diH2O
until supernatant became clear. Red stained mineralized layers produced by differentiated cells
were observed macroscopically and under inverted microscope. For the extraction and quanti-
fication of the ARS, 10% acetic (ARK2183, Sigma-Aldrich) was added to the wells. Cells and
mineral deposits were scraped from the plate and collected, heated at 85˚C for 10 minutes and
immediately transferred to ice, for 5 minutes. The samples were centrifuged, and individual
absorbance values were measured at 405 nm, along with a standard curve for the calculation
ARS concentration (μM).
Chondrogenic differentiation protocol: MSCs were suspended at 2x104 viable cells/well
of 96-well plate, and let to adhere for 48 hours. Chondrogenic culture medium (StemPro
Chondrogenesis Differentiation kit, A10071-01, Gibco) was added to each well. Control wells
remained in FBS or hUCBP supplemented media. Media was replaced every other day in
both groups. After 14 days, wells were stained with Alcian Blue to assess for Proteoglycan’s
synthesis by differentiated chondrocytes and Sulfated Glycosaminoglycans (GAGs) produc-
tion was quantified using the Blyscan™ Glycosaminoglycan Assay (Biocolor, UK). Alcian Blue
Staining (Qualitative): Cells were fixated with 4% formaldehyde, and stained with Alcian
Blue (A9186, Sigma) solution. Alcian Blue was discarded and wells were rinsed with acetic acid
3% (v/v). Acidity was neutralized with distilled water, and left in each well for visualization.
Differentiated cells were observed under inverted; GAGs Production (Quantitative): Sulfated
GAGs Assay was carried as per manufacturers’ instructions. Culture media was removed from
each well and reserved. GAGs in the ECM produced by cultured cells was extracted using
Papain (P3125 Sigma-Aldrich) and added to the previously collected supernatant, for total
GAGs quantification). After centrifugation and removal of cellular debris, Blyscan dye reagent
was added and incubated for 30 minutes, and then centrifuged to isolate the precipitated
coloured complex. The precipitate was dissolved and individual absorbance values were mea-
sured at 656 nm, along with a standard curve for the extrapolation of GAGs concentration
(μg/ml).
2.10. Statistical analysis
Statistical analysis was performed using the GraphPad Prism version 6.00 for Mac OS X
(GraphPad Software, La Jolla California USA). The experiments were performed in triplicates
and the results were presented as Mean ± SEM. Significant differences are also presented as
percentage difference, in which 100% viability corresponds to the non-treated cells. Dunnett’s
multiple comparisons test against control group (10% FBS) were performed by one-way
ANOVA supplemented with Tukey’s HSD post-hoc test. Quantitative data of β-Galactosidase
activity, Flow cytometry data and Multilineage differentiation assays were subjected to one-
way ANOVA test, followed by pairwise comparisons using Tukey’s HSD post hoc test. Statisti-
cal significance was established as P<0.05. Differences were considered statistically significant
at P< 0.05. Significance of the results is indicated according to P values with one, two, three
or four symbols (�) corresponding to 0.01�P<0.05; 0.001�P< 0.01; 0.0001�P<0.001 and
P<0.0001, respectively.
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3. Results
Results obtained are herein presented, and the most relevant findings highlighted.
3.1. Haematology auto-analyser, flow cytometry and microbiological
analysis of the umbilical cord blood (UCB) units
S1 Table (found in Supporting information) summarizes the data obtained by haematology
auto-analyzer, which includes the initial WBC count, performed before the volume reduction
with the AXP automated system (in cells x 109 per L) and the final WBC count (in cells x 109
per l), performed after the volume reduction procedure of the UCB samples. The obtained
mean values were 9.61 ± 2.96 x 109 cells/l and 29.42 ± 14.79 x 109 cells / l, respectively. The
samples presented an average of 66.17 ± 60.19 viable CD34+ cells/μl, with 93.13 ± 6.65%
viability, and 17.63 ± 7.27 x 109 viable CD45+/l, with 89.72 ± 4.96% viability (N = 13), demon-
strating individual variability considering the UCB hematopoietic stem cells concentration
and CD45+ / CD34+ cell viability. This individual variability has been previously reported in
UCB units processed by AXP automated system [41–43].
Considering the microbiological evaluation of the UCBP, all the samples were negative for
aerobic, anaerobic microorganisms and fungi, except for the sample hUCBP#5 which was posi-
tive for Actinomyces meyeri in anaerobiosis. Although contamination was identified in this
samples, all of the haematological parameters remained within the average counts (S1 Table,
hUCBP#5 sample). The bacterial contamination did not interfere with 1H-NMR analysis and
no statistical differences were observed between plasma sample hUCBP#5 and the mean values
calculated for the 13 plasma samples analysed (P<0.05) (S1 Table). However, hUCBP#5 was
excluded from the pool used for the in vitro validation, in order to prevent the cell culture con-
tamination, and the hUCBP pool included only 12 out of 13 samples analysed (N = 12).
3.2. Part I: Supplements metabolomic characterization
3.2.1. NMR spectroscopy. 1H-NMR spectra of all hUCBP and FBS samples were acquired
with water suppression using 1D NOESY and CPMG pulse sequences. The implementation of
1D NOESY has led to 1H-NMR spectra with improved solvent peak (at 4.70 ppm) suppression
but complex line shapes and highly overlapped resonances from the low molecular weight
metabolites and macromolecular components. To reduce the complexity of the spectra,
T2-edited CPMG experiments with appropriate T2 delays were used to attenuate the broad
signals from high molecular weight species and facilitate the identification of small molecular
components. The average 1H (CPMG) NMR spectra of hUCBP and FBS samples are shown in
Fig 1A and Fig 1B, respectively. The assignment of the resonance signals in the spectra was
based on results obtained from various 1D and 2D (1H/1H COSY, 1H/1H TOCSY, 1H/13C
HSQC) NMR experiments and reference data [51, 52]. Characteristic resonance signals of
metabolites identified in 1H -NMR spectra of hUCBP and FBS samples are labelled in Fig 1.
The analysis of 1H-NMR spectra has allowed the identification and quantification of a number
of metabolites in hUCBP and FBS listed in Table 2.
The presence of essential amino acids useful for protein metabolism and protein synthesis
(alanine, arginine, glutamine, glutamate, isoleucine, histidine, leucine, lysine, phenylalanine,
proline, tyrosine, and valine), organic acids and derivatives (lactate, β-hidroxibutirate, ethanol,
formate, creatine), glucose (α glucose and β glucose), lipids, and nucleotides (adenosine, uri-
dine, guanosine species) were detected in the hUCBP, FBS_I, and FBS_II samples spectra. The
relative integral intensity of characteristic signals in 1H-NMR spectra of hUCBP samples and
FBS samples (both FBS_I and FBS_II) was used to quantify the detected metabolites. The
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Fig 1. MHz 1H-NMR spectra of FBS_I and FBS_II and hUCBP. Average 600 MHz 1H-NMR spectra (A) of FBS_I, and FBS_II and
(B) hUCBP samples.
https://doi.org/10.1371/journal.pone.0203936.g001
Table 2. Relative quantitative distribution of metabolites observed in the 1H-NMR spectra of hUCBP, FBS_I, and FBS_II samples.
Metabolites Code Group Chem. Shifts (ppm) hUCBP FBS_I FBS_II
1-Methylhistidine 1_Me-His CH 7,80–7.86 0,47 ± 0,23 0,43 ± 0,05 0,34 ± 0,08
3-Methylhistidine 3-Me-His CH 7,60–7,68 0,47 ± 0,21 0,43 ± 0,06 0,31 ± 0,09
Acetate Ace CH3 1,93 0,14 ± 0,05 0,18 ± 0,01 0,18 ± 0,02
Adenosine ADP/ATP CH 8,22 0,48 ± 0,21 0,41 ± 0,06 0,28 ± 0,09
Alanine Ala CH3 1,46 0,35 ± 0,12 0,86 ± 0,04 0,89 ± 0,02
Bile Acids BA CH3 0,50–0,75 0,37 ± 0,16 0,26 ± 0,02 0,21 ± 0,07
Choline Cho NCH3 3,24 0,13 ± 0,04 0,12 ± 0,00 0,11 ± 0,01
Citrulline Citr CH2 3,12 0,25 ± 0,07 0,20 ± 0,00 0,17 ± 0,03
Creatine Cr CH3 3,04 0,22 ± 0,16 0,35 ± 0,01 0,38 ± 0,01
Ethanol/ Hydroxybutyrate EtOH/HB CH3 1,21 0,31 ± 0,11 0,62 ± 0,02 0,22 ± 0,01
Formate For CH 8,52 0,53 ± 0,21 0,41 ± 0,06 0,29 ± 0,09
Glutamate/ Glutamine Glu/Gln CH2 2,34 0,85 ± 0,30 1,40 ± 0,01 1,44 ± 0,07
Histidine His CH 7,74 0,23 ± 0,11 0,20 ± 0,03 0,18 ± 0,04
Lactate Lac CH 4,14 1,01 ± 0,25 3,33 ± 0,10 3,25 ± 0,25
Lipids Lip CH3 0,8–0,9 0,62 ± 0,18 0,59 ± 0,00 0,66 ± 0,01
Lysine/Arginine Lys/Arg CH/CH2 1,6–1,8 0,49 ± 0,15 0,50 ± 0,01 0,47 ± 0,06
Phenylalanine PheAla CH3.5 7,44 0,16 ± 0,07 0,15 ± 0,02 0,13 ± 0,02
Prolina Pro CH 4,2 0,44 ± 0,16 0,64 ± 0,06 0,80 ± 0,15
Threonine Thr CH 4,26 0,32 ± 0,13 0,51 ± 0,05 0,57 ± 0,04
Tryptophan Try CH7 7,56 0,24 ± 0,11 0,20 ± 0,03 0,15 ± 0,04
Tyrosine Tyr CH2.6 6,9 0,13 ± 0,11 0,12 ± 0,03 0,08 ± 0,05
Valine/ Leucine/ Isoleucine Val/Leu/Ile CH3 0,9–1,1 0,30 ± 0,09 0,69 ± 0,02 0,77 ± 0,04
α-Glucose α-Glu CH(H1) 5,28 2,93 ± 0,63 0,47 ± 0,02 0,42 ± 0,01
β-Glucose β-Glu CH(H1) 4,68 3,40 ± 0,70 0,73 ± 0,15 0,69 ± 0,05
https://doi.org/10.1371/journal.pone.0203936.t002
Human umbilical cord blood plasma as an alternative to animal sera
PLOS ONE | https://doi.org/10.1371/journal.pone.0203936 October 10, 2018 12 / 35
results allowed us to estimate the relative quantitative distribution of metabolites in all studied
samples. The metabolic profiles of the FBS samples (both FBS_I and FBS_II) were found to be
very similar but demonstrated some differences when compared to analysed hUCBP samples.
The average data for the metabolites distribution in hUCBP, FBS_I and FBS_II samples are
graphically presented in Fig 2.
The results have shown that the major difference between the metabolic profiles of hUCBP
and FBS samples is due to the different content of glucose, lactate, glutamate, alanine and
branched chain amino acids (see Table 2 for detailed relative quantities). Significantly higher
levels of glucose (α glucose and β glucose) and lower levels of lactate were found for the
hUCBP than for FBS samples. The analysis of 1H-NMR spectra further revealed an increased
level of alanine, glutamate, isoleucine, leucine and valine in both commercial FBS (FBS_I and
FBS_II) when compared to hUCBP samples. This seems to be the main difference between the
amino acids profiles of hUCBP and FBS. Increased levels of alanine and glutamine can be
identified in the commercial FBS sera. Apart from the amino acids discussed above, all hUCBP
samples were found to have similar or slightly higher contents of arginine, citrulline, choline,
histidine, 1(3)-methyl-histidine, lysine, phenylalanine, tryptophan and tyrosine, as well as of
nucleotides (δ = 8.4–7.8 ppm), lipids (δ = 0.5–0.9; 1.3; 5.3 ppm), choline and formate when
compared to the FBS samples analysed.
Fig 2. Relative quantitative distribution of the metabolites in hUCBP, FBS_I and FBS_II. Results presented as Mean ± SEM. Symbols reflect differences
between hUCBP and FBS_I (�), hUCBP and FBS_II (#), and FBS_I and FBS_II (+), where the numbers of symbols represents the P value (1 symbol:
0.01�P�0.05; 2 symbols: 0.001�P<0.01; 3 symbols: 0.0001�P<0.001; 4 symbols: P<0.0001).
https://doi.org/10.1371/journal.pone.0203936.g002
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3.2.2. PCA of hUCBP samples. PCA was used to classify the NMR spectral data and
revealed factors contributing to the variability between the three groups of data sets. The NMR
data in the spectral area between 0.5 and 9.0 ppm was analysed with the water and citric acid
spectral regions always excluded prior to PCA analysis and provided as input to the PCA algo-
rithm. The algorithms extracts are the so called Principal Components (PC) that explain data
similarity and variability. The hUCBP was first analysed independently of the FBS samples.
The 1H-NMR spectral data of all hUCBP samples (normalized by the total sum of the integral
intensities) are plotted in Fig 3A. The observed variations are confirmed by the 2D (PC1 vs.
PC2) score plot in Fig 3B, where the hUCBP samples are clearly scattered and one typical out-
lier sample is also detected. Note that the first two PCs accumulated more than 97% of data
variance (PC1 has 91.7% and PC2 has 5.9% amount of variance), therefore they are sufficient
features to represent the data. The corresponding loadings plots for PC1 and PC2 in Fig 3C
illustrate that sugars and lactate content are the main metabolites responsible for the diver-
gence between the hUCBP samples.
3.2.3. PCA of hUCBP and FBS samples (FBS_I and FBS_II). Statistical analysis was fur-
ther applied to the 1H-NMR spectra of all samples in order to identify the source of variability
between the metabolic profiles of hUCBP, FBS_I and FBS_II. The 1H-NMR spectral trajecto-
ries of the hUCBP samples (blue colour) and FBS samples (red colour) groups are plotted in
Fig 4A. Visual data inspection shows the higher levels of glucose but lower of lactate, ethanol,
acetates, and several amino acids (alanine, glutamate, valine, leucine, and isoleucine) in the
hUCBP when compared to the FBS samples. A matrix with 19 columns (correspond to the
samples) over the spectral area between 0.5 and 9.0 ppm with the water and citric acid spectral
regions excluded was provided as input to the PCA algorithm. The 2D (PC1 vs. PC2) PCA
score plot is depicted in Fig 4B. The results illustrated the close similarity of FBS_I and FBS_II
data sets (a well-defined cluster with overlapping samples) and revealed their separation from
the hUCBP data (a scattered cluster) particularly with respect to PC2. PC1 contains 70% and
PC2 23% of data variance, thus these two principal components are sufficient to represent the
data information content. The corresponding loadings plots (Fig 4C) provide evidence that
glucose, lactate and acetates are the dominant metabolites contributing to the dissimilarity
Fig 3. Metabolomic analysis of hUCBP samples. (A) 1H-NMR spectral trajectories of the hUCBP samples; (B) 2D (PC1 vs. PC2) PCA score plot shows that hUCBP
data are well clustered (i.e. there is high similarity between the donor samples) with exception of one donor (considered as an outlier) and (C) corresponding loadings
plots illustrate that sugars and lactate content are the main metabolites responsible for the divergence between the hUCBP samples.
https://doi.org/10.1371/journal.pone.0203936.g003
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between the human plasma (hUCBP) and bovine sera (FBS_I and FBS_II) data sets. Loading
plots around zero line suggest close behaviour of the metabolites profiles in the spectral
region from 9.0 ppm to 5.3 ppm of the three groups of samples (hUCBP, FBS_I and FBS_II
samples). These results coincide with those obtained from the 1H-NMR spectral analysis of the
samples.
3.2.4. PCA of hUCBP samples and FBS samples (FBS_I and FBS_II) excluding glucose
and lactate spectral areas. In order to assess intrinsic variations in the content of proteino-
genic amino acids, lipids and organic acids and derivatives between hUCBP, FBS_I and
FBS_II samples, the same PCA analysis was applied on the 1H-NMR data after exclusion of
glucose (5.28 ppm—4.65 ppm; 4.17 ppm—3.24 ppm) and lactate (1.37 ppm—1.32 ppm) spec-
tral areas. The 1H-NMR spectral trajectories are plotted in Fig 5A and the PCA score plot is
shown in Fig 5B. The hUCBP samples analysis was less scattered, while the FBS_I and FBS_II
samples continued to behave as a well-shaped cluster. This observation suggests that glucose
and lactate concentrations significantly vary between the hUCBP samples of different donors
and their exclusion increased the metabolite profiles proximity. The hUCBP and FBS (FBS_I
and FBS_II) samples clusters diverge mainly in the PC2 score (representing only 13% of data
variance) and have a very close PC1 score (representing 80% of data variance). The respective
loading plots (Fig 5C) confirm these results. They illustrate that the main differences between
the hUCBP and FBS data are due to different concentrations of particular amino acids (ala-
nine, glutamate, isoleucine, leucine, and valine) and organic acids and derivatives (N-acetyl
residues, 3-hydroxybutyric acid, and creatine) in the spectral region from 3.3 ppm to 0.5 ppm.
From the spectral intervals where the loading plots are close to zero, i.e. from 9.0 ppm to
3.3 ppm, with the glucose spectral area excluded, it can be concluded that the metabolites pro-
files of the three groups (hUCBP, FBS_I and FBS_II samples) are similar.
PCA analysis was performed in three different scenarios based only on the first two Princi-
pal Components (PC). Fig 6 illustrates that PC1 and PC2 accumulate more than 90% of data
variability and therefore their statistical significance is reliable.
Fig 4. Metabolomic analysis of hUCBP and FBS samples. (A) 1H-NMR spectral trajectories of the hUCBP samples (blue colour) and FBS (FBS_I and FBS_II samples)
(red colour) groups; (B) 2D (PC1 vs. PC2) PCA score plot shows close similarity of FBS_I and FBS_II data (a well-defined cluster with overlapping samples) and a
separation from the hUCBP data and (C) corresponding loadings plots illustrate that glucose, lactate and acetates are the main metabolites contributing to the
dissimilarity between the human plasma (hUCBP) and bovine sera (FBS_I and FBS_II) samples. Loading plots around zero line suggest close behaviour of the
metabolites profiles in the spectral region from 9.0 ppm to 5.3 ppm of the three groups of samples (hUCBP, FBS_I and FBS_II samples).
https://doi.org/10.1371/journal.pone.0203936.g004
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3.3. Part II: In vitro validation
3.3.1. Cell viability assessment. The application of hUCBP as a culture medium supple-
ment for in vitro culture and expansion of hMSCs was evaluated using UC-MSCs and DPSCs.
Fully characterised cell lots were used for the purpose. PrestoBlue1 viability test was
Fig 5. Metabolomic analysis of hUCBP and FBS samples excluding glucose and lactate spectral areas. (A) The 1H-NMR spectral trajectories; (B) the PCA score plots
shows that the hUCBP samples (a well-defined cluster) and the FBS samples (also a well-defined cluster) are less divergent now (they all have a very close PC1 score) and
(C) respective loading plots illustrate that the main differences between the hUCBP and FBS data are due to different concentrations of particular amino acids (alanine,
glutamate, isoleucine, leucine, and valine) and organic acids and derivatives (N-acetyl residues, 3- hydroxybutyric acid, and creatine) in the spectral region from 3.3 ppm
to 0.5 ppm. For spectral area between 9.0 ppm to 3.3 ppm (with excluded glucose) the metabolites profiles of the three groups (hUCBP, FBS_I and FBS_II samples) are
very similar.
https://doi.org/10.1371/journal.pone.0203936.g005
Fig 6. PC contributions for data representation.
https://doi.org/10.1371/journal.pone.0203936.g006
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undertaken at determined time points and the supernatant absorbance was measured, normal-
ized and corrected according to manufacturers’ instructions. Corrected absorbance values are
presented in S2 Table, in Supporting information.
The FBS_II supplemented samples were set as the reference control for the behaviour of
hUCBP test samples. Obtained results are graphically presented in Fig 7 and absorbance data
is available in S2 Table, in Supporting information.
At 24 hours, UC-MSCs cultures with hUCBP at 4% depicted significantly superior mea-
surements concerning % of cell viability and absorbance, when compared to 10% FBS_II, cor-
responding to a 200.02% increase over the FBS_II control at that time point. DPSCs presented
similar behaviour in most of the tested groups, with no significant differences from the FBS_II
control. Here, only the hUCBP 8% group presented inferior measurements (76.28% of cell via-
bility. At 72 hours in culture, UC-MSCs in both hUCBP 2% and hUCBP 4% raised the absor-
bance to 73.59% and 67.86% over the matched control, respectively. In the DPSCs set, all
groups performed superiorly, to the FBS control. In the following time point of 120 hours, no
statistical differences were found between the tested groups, for hMSCs from both sources.
Maximum measurements were obtained at 168 hours in culture with UC-MSCs at hUCBP 6%
and hUCBP 8%, matching 10% FBS_II. On the other hand, hUCBP 4% remained superior to
10% FBS_II control. In the DPSCs, only hUCBP 6% performed comparably to 10% FBS_II,
with all other tested groups presenting inferior corrected absorbances.
Both hMSCs types reached the plateau before 216 hours in culture, and hence, metabolic
rates (and resazurin reduction) arrested. In all cell culture groups, including the 10% FBS_II, a
decrease of the corrected absorbance measurements was observed. Only UC-MSCs cultured in
hUCBP 4% supplemented medium sustained activity matching the control.
Absorbance intensity is correlated to the metabolic activity of cells and not directly to their
number, but superior number of cells relate to increased viability readings. Retrieved cells
numbers and viability (total cell numbers and life cell numbers recovered) by Trypan blue
exclusion assay at 24 hours (1day), 72 hours (3 days), 120 hours (5 days), 168 hours (7 days),
and 216 hours (9 days) are presented in Table 3.
3.3.2. Senescence and apoptosis. The assessment of β-Galactosidase activity as an indica-
tor of senescent decline of hMSCs’ populations cultures in hUCBP supplemented media
revealed no striking differences when compared to FBS supplemented control media, for both
assayed populations (Fig 8A and S3 Table, in Supporting information). Exception was noted
for cultured UC-MSCs, at 5 days in culture, where FBS supplemented groups displayed
increased β-Galactosidase activity when compared to 4 and 8% hUCBP supplemented groups.
Annexin-V/ PI assay was employed for the detection and definition of apoptosis in cultured
cells. Early apoptosis is characterized by plasma membrane reorganization, detected by posi-
tive staining for Annexin V, while later stage of apoptosis presents membrane damage, there-
fore PI can bind to DNA in cytoplasm resulting in positive staining for both Annexin V and PI
[53]. Cells cultured under hUCBP or FBS supplementation revealed no significant differences
in Annexin-V or PI staining, with exception to hUC-MSCs cultured in hUCBP 8% supplemen-
tation (�), which presented increased early apoptosis events, and decreased overall cell viability
over the remaining UC-MSCs’ groups (% Viable cells (An- PI-): 99,50 ± 0,06; 99,40 ± 0,06;
92,93 ± 0,52; 99,37 ± 0,13, and % Early apoptosis (An+PI-): 0,29 ± 0,03; 0,40 ± 0,04; 6,42 ± 0,53;
0,47 ± 0,07, for 4%, 6%, 8% hUCBP and 10% FBS supplemented media) (Fig 8B and S4 Table
in Supporting information).
3.3.3. MSCs’ Phenotype identity. The surface marker profiles of UC-MSCs and DPSCs
cultured in either hUCBP or FBS supplemented media were assessed though Flow Cytometry.
MSCs populations presented characteristic MSCs phenotypical markers in all culturing condi-
tions (Fig 9 and Table 4), and although some slight differences are noted, populations remain
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Fig 7. Corrected absorbance readings hUC-MSCs and hDPSCs viability. (A) Corrected absorbance at each assessed time point of the hUC-MSCs cultured in 10%
FBS_II, hUCBP 4%, 6% and 8%. (B) Corrected absorbance at each assessed time point of the hDPSCs cultured in 10% FBS_II, hUCBP 4%, 6% and 8%. Values are
presented as Mean ± SEM. Statistically differences were analysed for each hUCBP test samples versus control (10% FBS_II supplemented medium) and presented with
one to four symbol (�) (�: 0.01�P�0.05; ��: 0.001�P<0.01; ���: 0.0001�P<0.001; ����: P<0.0001).
https://doi.org/10.1371/journal.pone.0203936.g007
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within the� 92% positive population for CD90, CD105 and CD44, and� 2% negative stain-
ing for CD34, CD11b, CD19, CD45 and MHC II. Remarks are to be made regarding the CD90
expression by hDPSCs, which presented only 87–91% positive population, contrasting with
99–100% expressing population of hUC-MSCs.
3.3.4. Gene expression. Gene expression was performed through RT-qPCR analysis. Total
RNA was successfully extracted from cultured hMSCs (S5 Table, in Supporting information)
and specific genes’ expression assessed, after 5 days in specific culturing media conditions.
CD34 and Sox2 were undetected in any of the samples from hUCBP or FBS cultured cells, in
either population. Strong expression (<29 Cq) of CD105 and CD166, and moderate expres-
sion (30–35 Cq) of CD115 were detected in all assayed groups, and no change in expression
was observed in differently supplemented UC-MSCs and DPSCs cultures. Particular changes
in fold-expression of specific genes was identified in hMSCs from each source (Fig 10 and S6
Table, in Supporting information). In UC-MSCs, CD90 and MHC class I were down-regu-
lated in all hUCBP supplemented groups (although maintaining a strong expression), and
moderately expressed OCT-4 was down-regulated in the highest % supplementation groups (6
and 8%). Expression of MHC class II sequence was not detected in 10% FBS supplemented cul-
tures, while it became weakly expressed (>35 Cq) in hUCBP supplemented groups. In DPSCs,
strong and moderate expression of CD73 and OCT-4, respectively, was observed in 10% FBS
and up-regulated in hUCBP supplementation groups. Contrarily, weak expression of MHC
class II was detected in 10% FBS supplemented hDPSCs, that tended to attenuate (down-regu-
late) in hUCBP supplemented groups.
3.3.5. Multilineage differentiation. Osteogenic differentiation—Macroscopic observa-
tion revealed strong Alizarin Red S staining in the FBS supplemented Osteogenic media
groups, in both UC-MSCs and DPSCs. All Undifferentiated control groups presented weak
ARS staining. Whereas, in all hUCBP supplemented Osteo-differentiation groups, in both cell
types, weak ARS staining was observed, not empirically distinguishable from respective control
groups. Observation suggest an effective osteo-differentiation and mineral matrix deposition
by hMSCs cultures in Osteogenic media containing FBS, while hUCBP supplemented groups
did not differentiate towards the intended lineage, after 21 days in specific culture (data not
shown). ARS binding quantification confirmed these observations (Fig 11A). Some of the
Table 3. Retrieved cell numbers (x 103) assessed by Trypan Blue exclusion dye assay of hMSCs (UC-MSCs and DPSCs), in the presence of supplemented medium
with FBS_II or variable concentrations of hUCBP after 24 hours (1day), 72 hours (3 days), 120 hours (5 days), 168 hours (7 days), and 216 hours (9 days) incubation.




FBS 10% hUCBP 2% hUCBP 4% hUCBP 6% hUCBP 8%
24 h (1 day) 4,23 ± 6,35 4,46 ± 1,64 6,28 ± 2,76 5,97 ± 1,08 5,50 ± 0,97
72 h (3 days) 11,09 ± 0,73 19,94 ± 7,36 20,70 ± 9,17 13,82 ± 24,11 16,24 ± 5,40
120 h (5 days) 94,92 ± 5,40 83,54 ± 5,46 108,48 ± 24,60 118,41 ± 28,99 98,87 ± 3,60
168 h (7 days) 210,17 ± 11,24 173,46 ± 28,12 229,63 ± 23,09 221,25 ± 16,71 174,57 ± 3,11
216 h (9 days) 200,00 ± 14,98 166,00 ± 11,53 216,00 ± 23,69 211,00 ± 12,53 182,00 ± 3,00
DPSCs
FBS 10% hUCBP 2% hUCBP 4% hUCBP 6% hUCBP 8%
24 h (1 day) 18,16 ± 1,82 24,82 ± 2,86 25,82 ± 6,14 24,96 ± 4,37 16,95 ± 1,67
72 h (3 days) 39,96 ± 23,12 47,26 ± 10,85 49,23 ± 6,39 52,42 ± 9,14 36,88 ± 5,28
120 h (5 days) 163,13 ± 17,46 112,09 ± 0,96 227,88 ± 3,98 243,48 ± 16,68 180,14 ± 14,66
168 h (7 days) 255,78 ± 16,77 110,72 ± 22,56 215,30 ± 15,45 245,15 ± 20,21 204,28 ± 9,18
216 h (9 days) 250,00 ± 7,23 104,00 ± 10,21 191,00 ± 11,59 231,00 ± 7,51 224,00 ± 10,82
https://doi.org/10.1371/journal.pone.0203936.t003
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differentiating groups presented no statistical difference towards the respective undifferenti-
ated controls (S7 and S8 Tables, in Supporting information). Furthermore, the semi-quantita-
tive analysis points towards an increased efficiency in the Osteogenic differentiation of DPSCs
when compare to UC-MSCs, under the same differentiating conditions (2299.31 ± 7.35 μM
and 1449.57 ± 0.00 μM of ARS, respectively).
Adipogenic differentiation—Microscopic observation of ORO stained cells evidenced
comparable lipid droplets accumulation in the FBS supplemented Adipogenic media groups,
in both UC-MSCs and DPSCs. Controls presented occasional lipid droplets accumulation. All
hUCBP supplemented Adipo-differentiation groups presented similar differentiation pattern
to FBS supplemented groups, amongst all groups of UC-MSCs and DPSCs. Cellular popula-
tions maintained in hUCBP presented lipid droplets accumulation in the cytoplasm (data not
shown). Spectrophotometric measurement of ORO staining indicated no significant difference
between different supplementation levels and/or FBS, within each cell type. However, control
groups maintained in hUCBP indicate significantly superior ORO staining over FBS supple-
mented controls (Fig 11B and S9 and S10 Tables, in Supporting information).
Fig 8. Senescence and Apoptosis: A) Senescence - β-Galactosidase activity (OD405nm) on UC-MSCs and DPSCs at 3, 5 and 7
days. Results Presented as Mean ± SEM. Significance of the results is indicated according to P values with one, two, three or four
of the symbols (�) corresponding to 0.01�P<0.05; 0.001�P< 0.01; 0.0001�P<0.001 and P<0.0001, respectively; B) Apoptosis:
Annexin-V/ PI detection of UC-MSCs (upper panel) and DPSCs (lower panel). Results Presented as Mean ± SEM. Dot Plots of
the correspondent data are presented at the right side of the panels. Top left quadrants match annexin V negative and PI positive
cells; Top right quadrants correspond to dead cells that express annexin V and PI positive; Bottom right quadrants pairs with
apoptotic cells that express annexin V positive and PI negative; and for last, bottom left quadrants, viable cells that express
neither annexin V or PI.
https://doi.org/10.1371/journal.pone.0203936.g008
Fig 9. Surface marker expression for MSCs’ identity of hUC-MSCs and hDPSCs, assessed by Flow cytometry.
https://doi.org/10.1371/journal.pone.0203936.g009
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Chondrogenic differentiation—Groups cultured in Chondrogenic Differentiation media
all presented marked light blue staining under macroscopic and microscopic observation,
indicating proteoglycan deposition. Control groups from DPSCs in UCBP and FBS remained
unstained, indicating no differentiation, as did UC-MSCs in FBS supplemented media. Con-
trol groups of UC-MSCs maintained in hUCBP for the assay period presented mild Alcian
blue staining and aggregation, suggesting formation of chondrogenic pellets and deposition of
proteoglycan rich matrix (data not shown). UC-MSCs and DPSCs maintained in FBS supple-
mented control media presented no difference in terms of GAGs production, and cells transi-
tioned to differentiating media after 3 days showed increased GAGs production,
demonstrating differentiation towards a chondrogenic phenotype, with no significant differ-
ences between cell types (Fig 11C and S11 and S12 Tables, in Supporting information). Cells
expanded in hUCBP at different concentrations and transitioned to Chondrogenic differentia-
tion media, displayed comparable GAGs production. In the DPSCs, cell maintained in hUCBP
for the 14 days of the differentiation period did not differ from the ones maintained in FBS
10%. Undifferentiated controls of UC-MSCs’ maintained in the hUCBP supplemented media
Table 4. Surface marker profiles of hUC-MSCs and hDPSCs cultured in either hUCBP or FBS supplemented media, assessed though Flow Cytometry. �NEG+ cock-
tail corresponds to anti-CD34; -CD11b; -CD19; -CD45; and -MHC II antibodies.
Surface Markers hUC-MSCs
hUCBP 4% hUCBP 6% hUCBP 8% FBS 10%
CD90+ 99,90 ± 0,00 99,83 ± 0,03 99,87 ± 0,03 99,23 ± 0,12
CD105+ 99,97 ± 0,03 99,77 ± 0,03 99,87 ± 0,03 99,07 ± 0,09
CD44+ 99,47 ± 0,09 99,40 ± 0,15 99,27 ± 0,20 95,70 ± 1,65
NEG+� 0,05 ± 0,01 0,14 ± 0,04 0,25 ± 0,14 0,13 ± 0,08
hDPSCs
hUCBP 4% hUCBP 6% hUCBP 8% FBS 10%
CD90+ 90,23 ± 0,45 90,70 ± 0,15 90,67 ± 0,07 90,50 ± 0,35
CD105+ 99,90 ± 0,00 100,00 ± 0,00 99,97 ± 0,03 99,30 ± 0,06
CD44+ 99,97 ± 0,03 99,80 ± 0,00 99,83 ± 0,03 99,80 ± 0,00
NEG+� 0,37 ± 0,03 0,52 ± 0,05 0,52 ± 0,09 0,13 ± 0,04
https://doi.org/10.1371/journal.pone.0203936.t004
Fig 10. Quantitative RT-PCR of UC-MSCs and DPSCs cultured in hUCBP or FBS supplemented media. RQ: relative quantification (fold change compared to the
FBS 10% group), in mean fold change ± SEM.
https://doi.org/10.1371/journal.pone.0203936.g010
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demonstrated a tendency to produce increased GAGs, when compared to controls, with mean
values approaching differentiated groups, and not being significantly different from these.
Fig 11. Multilineage differentiation: A) Osteogenic differentiation: Alizarin Red S concentration (μM) after 21 days;
B) Adipogenic differentiation: Oil Red O (OD570nm) after 14 days; and C) Chondrogenic differentiation: Sulfated
GAGs production (μg/mL) after 14 days, assessed by Blyscan™ Glycosaminoglycan Assay (Biocolor, UK). Control:
Undifferentiated control; Results Presented as Mean ± SEM. a: significantly different from undifferentiated group
within the same media condition and cellular population; b: undifferentiated control group significantly different from
undifferentiated FBS 10% group, within the cellular population; c: differentiated group significantly different from
differentiated FBS 10%, within the cellular population.
https://doi.org/10.1371/journal.pone.0203936.g011
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4. Discussion and conclusions
In light of the observations from this study, the option of utilizing hUCBP as a potential
replacement to FBS supplementation for hMSCs expansion gains further support. The first
part of the study focused on the characterization the metabolite composition of hUCBP and its
comparison to conventionally utilised FBS, to address its suitability as a culture medium sup-
plement and FBS substituent. In primary samples analysis, individual variations were observed
concerning the CD34+/CD45+ and WBC cells counting, where different donors contribute to
a wide range of values. One of the samples was detected as contaminated by anaerobic agent
Actinomyces meyeri (hUCBP#5), which reinforces the need for thorough quality control of
hUCBP samples before usage for cellular therapies preparation. To the authors’ knowledge,
this is the first extensive comparative study on the metabolomic profile of FBS and hUCBP.
Previous published work contributed to a deeper understanding on the growth factor, cytokine
and chemokines content of hUCBP, suggesting that it could play a relevant role in advanced
therapies development [8].
Within hUCBP samples, glucose and lactate are the major contributors to inter-samples
metabolite composition variations. Overall, these observations suggest that, similarly to FBS
supplements, the hUCBP are not homogeneous, and present great individual variability, thus
requiring to be primarily homogenized before being used in cell-based therapies preparation
[41–43]. Hence, the composition of pooled hUCBP batches is well suited for standardization,
to which this work aims to contribute with relevant data in terms of individual samples com-
positions. This will aid in the definition of reference ranges of key components for the approval
and release of representative batches, targeting at the reduction of inter-batch variability.
In addition to the detailed definition of individual samples and pooled plasma batch com-
position as well as the standardization of reference ranges, other concerns must be observed
regarding hUCBP quality and safety analysis. Strict control of potential infectious diseases
transmission is required at the various steps of the process. One limitation from the necessity
of pooling of multiple donor samples is the increased potential risks of infection via donors’
hUCBP. To counterbalance this risk, control step reinforcement is advised when aiming at
therapeutic applications, with further monitoring of individual samples upon collection and
following homogenization/ pooling process.
Comparatively, metabolite profiles of both supplements present distinct features, as demon-
strated by NMR spectroscopy and subsequent PCA analysis. The main difference between the
metabolic profiles of the two proposed supplements was due to the significantly higher levels
of glucose (both α and β glucose) and lower of lactate in the hUCBP. The increased glucose
content in hUCBP was attributed to the function of UCB to provide energetic and other meta-
bolic support for the foetus during intrauterine development. The observed variation in the
glucose levels throughout hUCBP samples has also been ascribed to the particular diet and
health conditions of the different donors, as described by other researchers [41–43]. The pres-
ence of anticoagulant citrate phosphate dextrose solution (CPD) [composed of 2.63g of
sodium citrate (dehydrate), 0.299 g of citric acid (monohydrate), 2.55g of dextrose (monohy-
drate) and 0.222g of sodium monobasic bisphosphate (monohydrate)] in the UCB sterile col-
lecting bag might have contributed to the high levels of carbohydrates, as well as of citric acid,
detected in 1H-NMR spectra of hUCBP. Culturing media usually contain varying concentra-
tions of glucose ranging from 1 to 4.5 g/l (5.6 to 25 mM). Glucose is a central source of energy
for hMSCs, and recently isolated cells normally benefit from high glucose during the first 48
hours in culture, as we have observed [12, 54, 55]. However, sustained elevated glucose con-
centrations may impair cellular functions, increase the intracellular calcium concentration
([Ca2+]i) and induce apoptosis [12, 47, 54]. It has also been demonstrated that high glucose
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stimulates the glucose-responsive gene thioredoxin-interacting protein (Txnip) in MSCs and
induces MSCs to a pro-apoptotic situation, which reduces their regenerative qualities after
chronic but not short-term exposure [55]. Nevertheless, high glucose contents must not always
be regarded as deleterious for hMSCs populations, as it appears to greatly improve survival in
severe hypoxia situations that are often associated with pathological events of ischemia and
stroke [56]. The glucose content of the culture medium is therefore of the utmost importance.
Increased levels of lactate are detected in FBS samples. In the haemoderived cellular culture
supplements, particularly those collected in perinatal stages, as is the case of FBS and hUCBP,
observed lactate levels strictly relate labor process and metabolic acidosis of the newborn, and
is an important indicator of intrapartum asphyxia [57]. Lactate is a product of anaerobic
metabolism of pyruvate (that mostly derives from supplied glucose), and accumulates in cellu-
lar culture supernatant during cell culturing, indicating a coexistence of both aerobic and
anaerobic bioenergetic pathways. We have recently focused on the characterization of the met-
abolic profile of these precise cellular populations, and have verified that small amounts (in
the μM range) of lactate are provided by basal culture media, and that this metabolite accumu-
lates steadily for up to 48 hours in the culture media (reaching concentration in the 100–
200 μM range) (Unpublished data). Most of the research targeting this topic focuses on lactate
production by cultured populations. Fewer references focus on the effects of the lactate on
these population, and mostly focus on its effects when accumulated in result of bioenergetic
production. Lactate is described to impact on cell proliferation, resulting in inhibition over
20mM lactate in the culture media [58], but little is commented on the effects of low concen-
tration of such metabolite. FBS samples assayed are commercially available and have been suc-
cessfully employed in the hMSCs culture, as represented by the control groups herein utilized.
Metabolomic analysis indicated increased increase relative amounts of lactate in these FBS
samples, when compared to the hUCBP. FBS and hUCBP are supplemented to culture media
in small percentages, ranging from 2–10% (in the presented experimental work) and hence
observed variations in the metabolite content are diluted in the final media formulation. Since
lower content in lactate is observed in the hUCBP samples, it is not expected to negatively
impact cell performance. Although lactate is recognised to affect MSCs proliferative and differ-
entiation features at high concentrations [59], FBS supplementation is not assigned to provide
inhibitory levels of lactate. Both FBS groups show similar metabolite profile that differ from
hUCBP samples in their high content of lactate, alanine, glutamine and branched chain amino
acids and lower of glucose. Similar or slightly different levels of important proteinogenic
amino acids, and of nucleotides, lipids, choline and formate were found in both samples.
These proteinogenic amino acids are proteins precursors, and thus play a crucial role in the
growth, proliferation and differentiation of hMSCs. The decreased content of alanine and glu-
tamine in the hUCBP samples could be theoretically compensated by adding culture media
supplements such as GlutaMAXTM (Thermo Fischer Scientific). This animal-origin free sup-
plement (L-alanyl-L-glutamine) is a dipeptide substitute for L-Glutamine and can be used as a
direct substitute for L-Glutamine at equimolar concentrations in mammalian and stem cell
culture with minimal or no adaptation [8, 60]. At a cellular level, there are many important
functions of amino acids such as glutamine, being essential as precursor for peptide and conse-
quently substrate for protein synthesis [61–63]. Choi and colleagues [64] reported on impor-
tance of adequate essential and non-essential amino acids in cell culture, as over
supplementation of the later was demonstrated to negatively affect MSCs proliferation. On the
other hand, increased levels of essential amino acids, with balanced non-essential amino acids
intake, were associated with increased cell proliferation. MSCs’ surface markers expression did
not seem to be affected by differential amino acid contents.
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Other minor differences in key proteins’ content are observed. Proline, a non-essential
amino acid, is overexpressed in FBS_II samples, and has been associated with suppressing
reactive oxygen species (ROS), thereby protecting mammalian cells from various stresses [65,
66]. FBS_I showed higher ethanol content in comparison to FBS_II. It has been reported that
stem cells are extremely sensitive to alcohol by-products such as acetaldehyde that induces
irreversible DNA mutation [67–69], and that it induces adipogenesis, resulting in cell death
[70]. In other reports, ethanol exposure interfered with pluripotency marker patterns [68].
Therefore, hUCBP’s lower content in ethanol arises as a beneficial point for the maintenance
of the regenerative potential of expanding hMSCs. This particular finding converges with our
preliminary experience in hMSCs in vitro proliferation and expansion, which supported the
choice of FBS_II to further study the comparative effect of hUCBP culture medium supple-
mentation [4–12, 29, 47].
The second part of the study aimed at the validation of hUCBP for the expansion of umbili-
cal cord and dental pulp derived mesenchymal stem cells. Proliferation and viability/metabolic
assays demonstrated that hMSCs were able to proliferate in 4%, 6% and 8% hUCBP supple-
mented culture media, and that metabolic rates observed (determined by Presto Blue day
reduction assay) were superior to those of DPSCs and UC-MSCs for up to 5 and 7 days,
respectively. At this point, cultured cells reached confluency, eliciting inhibitory signaling
within hMSCs populations, and hUCBP supplemented cultures increased metabolic rates
arrested. Zhang and colleagues reported that high glucose content in the MSCs culture media
(which is the most striking difference between hUCBP and FBS) resulted in impaired cellular
proliferation [71]. However, this study referred to glucose concentrations ranging from 11 to
20 mM (1.98 to 3.6 g/L, respectively), which exceeds the maximum concentration provided by
hUCBP supplemented media [10% FBS: 4,9mM; 4%hUCBP: 6,6mM; 6%hUCBP: 7,5mM; and
8%hUCBP: 8,6mM], and refers to 14 days of culturing, with no mention of passaging or cul-
ture confluency. Another study reports no deleterious effect on MSCs’ proliferation of 20-
30mM of glucose, but this parameter was only assessed at 48 hours of culturing [72]. The arrest
in proliferation rates observed in our study is directly linked to the confluent state of the cul-
tured populations, which are described to shift to inhibitory intercellular signaling (reflected
by metabolic rate decrease), due to close cell-to-cell contact. The same study [71], reported the
induction of cellular senescence in the high glucose groups. Cellular senescence of cultured
cellular populations reflect cellular aging in vivo, and this process is associated (although not
solely bound to) β-Galactosidase enzyme expression and activity [73]. We observed that short
term culturing (for up to 7 days) of passage 5 hMSCs in hUCBP supplemented media does not
elicit increased cellular senescence events, as reported by Chang and colleagues, for the same
time of assessment [74]. Again, contradictory observation may be due to the extreme glucose
concentrations and culturing periods reported [71]. Similarly, cultured populations were
assessed for apoptotic events, though the detection of Annexin-V and PI. Annexin V identifi-
cation indicates the externalization of the membrane phospholipid phosphatidylserine (PS),
which happens in the early stage of apoptosis. The positive of PI indicates access to intracellu-
lar genetic material, due to cell membrane compromise, which occurs either in the end stage
of apoptosis or in dead cells. Therefore, viable, early apoptotic, late apoptotic and dead cellular
populations can be distinguished [53]. We observed that culturing in hUCBP supplemented
media resulted in a dose related tendency for increased early apoptosis events (Annexin V+
and PI- cells) in both UC-MSCs and DPSCs. Supplementation with 8% hUCBP presented
seemingly inferior viable populations, with increased dead cells. These events were particularly
evident in UC-MSCs populations. High glucose contents are reported to induce oxidative
stress in exposed population, which drive MSCs towards apoptosis, through the activation of
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intrinsic cellular Caspase pathways [75]. These observations align with the apparent dose
dependent increase in early apoptosis observed herein [74].
The classification of specific populations as MSCs is related to the expression of a particular
immunophenotype. As such, it was agreed by the scientific community [2] that 95% of the can-
didate population ought to express CD105, CD73 and CD90, as well as to lack expression
(<5% positive) of CD45, CD34, CD14 or CD11b, CD79a or CD19 and MHC class II. Other
markers, such as CD44 are also identified in hMSCs populations. Cultured hMSCs populations
maintained >95% expression of CD105, CD44 and CD73, while remaining <2% positive for
CD34, CD11b, CD19, CD45 and MHC class II. Despite the ISCT’s guidelines for the classifica-
tion of MSCs populations, surface marker identity is a controversial topic. The obligatory
expression of high levels (>95%) of CD90 in addressed populations is not always confirmed,
while all other MSCs characteristics are verified, such as tri-lineage differentiation capacity
[64, 76]. We observed maximal expression of CD90 in hUC-MSCs, but lower levels are equally
reported [77]. The expression levels of CD90 have been related to MSCs their immunosup-
pressive capabilities, as Campioni and colleagues have disclosed [78]. Interestingly, qRT-PCR
revealed that, although remaining strongly expressed (in accordance to external marker
expression revealed by Flow Cytometry), CD90 depicted decreasing mRNA expression in
hUCBP cultured groups, which has been associated to decreased immunosuppressive capaci-
ties [78]. MSCs are also described to express MHC class I and, to a much smaller extent, MHC
class II [79]. DPSCs presented weak expression of MHC class II molecules, which attenuated
in xeno-free cultured groups. Contrarily, MHC class II was not detected UC-MSCs in FBS sup-
plemented groups, but became apparent in hUCBP cultured groups. These expression up- and
down-regulations are smooth, a did not reflect in the membrane expression of the molecule
[80]. MSCs are described to express pluripotency genes in resemblance to embryonic stem
cells. We confirmed c-kit and OCT-4 expression but were unable to detect Sox-2 mRNA. Simi-
larly to the character and degree of expression of surface markers, pluripotency genes expres-
sion provides conflicting reports [81, 82]. Distinct patterns of up- and down-regulation of
specific genes in UC-MSCs and DPSCs, along with the distinct responses verified in terms of
apoptosis and multilineage differentiation capacity, reinforce that differently sourced MSCs
respond differently to environmental cues, whether they are provided by their specific niches
or by ex-vivo culturing conditions. The replacement of FBS in the specific Osteo-differentia-
tion media presents a deleterious effect, as only minor staining was observed after incubation
with ARS (a Ca2+ binding dye). Quantification confirmed the inferior uptake in all hUCBP
groups, as compared to the FBS supplemented groups. Standard FBS supplemented differenti-
ation efficiency also support reported superior capacity from DPSCs to produce mineralized
matrix when compared to UC-MSCs [83]. Expansion of hMSCs in media supplemented with
hUCBP does not preclude their capacity to differentiate towards adipogenic phenotypes in
either cell type, when compared to FBS supplemented groups. The maintenance of UC-MSCs
and DPSCs in hUCBP supplemented media for 14 days induced lipid droplet deposition,
which although statistically inferior to cells maintained in differentiation media, was superior
to the respective FBS supplemented control. The presence of AGE (advanced glycation prod-
ucts, associated with high glucose levels) in culture media is associated to reduced MSCs’ dif-
ferentiation capacity [54]. Cramer and colleagues [75], also report impaired osteogenic and
chondrogenic potential of MSCs, but observed enhanced adipogenic tendency. Again, maxi-
mum concentration provided by hUCBP formulated media remains under the studied ranges
reported in literature, but similar effects were already observed in osteogenesis and adipogen-
esis of UC-MSCs and DPCSs. We do not observe the same inhibition in chondrogenensis.
Although high glucose is a marking feature oh hUCBP, other relevant components must be
addressed in its composition, such as growth factors, cytokines and chemokines [8].
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Preliminary assays demonstrate substantially increased levels of TGF-β 1–3 in hUCBP samples
when compared to FBS (7-, 2- and 28-fold increase in TGF-β 1, 2 and 3, respectively, data not
shown). TGF-β 1 is a strong modulator of TGFβ receptors expression, and thereof of chondro-
genesis of MSCs. Although the effects of high glucose are seemingly deleterious to this differ-
entiation pathway, it is associated with increased TGFβRII expression. The combination of
both factors (high concentration of glucose and TGF-βs) may attenuate the reported deleteri-
ous effect of glucose. We observed that chondro-differentiation efficiency was unaffected by
the expansion in hUCBP supplemented media, and that the maintenance of undifferentiated
control groups in hUCBP induced UC-MSCs to form chondrogenic-like pellets and produce
GAGs rich matrix. The differential response observed in the assessed cell population could
relate to the differentiation aptitude of MSCs derived from particular niches [83].
In conclusion, regardless of the discussed differences, FBS and hUCBP present relevant
similarities. This study reveals the existence of essential components (including glucose and
proteinogenic amino acids) for the growth and proliferation of hMSCs in both supplement
options. These observations suggest that hUCBP could be considered as an alternative to FBS
for in vitro production of hMSCs for cell-based therapies and for clinical applications. Never-
theless, investigation must deepen regarding the applicability of hUCBP through the entire
hMSCs production process, and studies are ongoing as for their suitability for the primary iso-
lation of cells from source tissues, as well as for cryopreservation and final formulations of
hMSCs derived therapeutic products. Further, we have observed some of the hUCBP composi-
tion on the MSCs features and capacities, such as in their differentiation potential, whose
impact on the therapeutic properties desired for specific diseases requires further
investigation.
Supporting information
S1 Table. UCB samples analysis. Initial WBC count, performed before the volume reduction
with the AXP automated system (cells x 109 per liter) and the final WBC count (cells x 109 per
liter), performed after the volume reduction procedure of the UCB samples, values obtained
by using the hematology auto-analyser (Ac T diff2™, Beckman Coulter, Inc.). Total number of
viable leucocytes (CD45+) per liter, the percentage (%) of viable leucocytes (CD45+), the total
number of viable CD34+ cells per μl, and the % of viable CD34+, measured by flow cytometry
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minimum (Min) values, standard deviation (SD) and the standard error of the mean (SEM) of
N = 13 are also presented. �Count using the hematology auto-analyzer. #Extrapolated values
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after volume reduction and before cryopreservation and tested for microbiological contamina-
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S2 Table. Corrected absorbance assessed by PrestoBlue viability assay of hMSCs
(UC-MSCs and DPSCs), in the presence of supplemented medium with FBS_II or variable
concentrations of hUCBP for up to 9 days. Results presented as Mean ± SEM.
(DOCX)
S3 Table. β-Galactosidase activity assay (OD405nm) on UC-MSCs and DPSCs at 3, 5 and 7
days. Results Presented as Mean ± SEM.
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(DOCX)
S8 Table. Statistical significance in Alizarin Red S concentration (μM) after 21 days. C:
Undifferentiated control; D: Osteogenic Differentiation. Significance of the results is indicated
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0.01�P<0.05; 0.001�P< 0.01; 0.0001�P<0.001 and P<0.0001, respectively; ns, not significant.
(DOCX)
S9 Table. Adipogenic differentiation. Oil Red O (OD570nm) after 14 days. Control: Undiffer-
entiated control; Adipo Diff: Adipogenic Differentiation. Results Presented as Mean ± SEM.
(DOCX)
S10 Table. Statistical significance in Oil Red O (OD570nm) after 14 days. C: Undifferentiated
control; D: Adipogenic Differentiation. Significance of the results is indicated according to P
values with one, two, three or four of the symbols (�) corresponding to 0.01�P<0.05;
0.001�P< 0.01; 0.0001�P<0.001 and P<0.0001, respectively; ns, not significant.
(DOCX)
S11 Table. Chondrogenic differentiation. Sulfated GAGs production (μg/ml) after 14 days,
assessed by Blyscan Glycosaminoglycan Assay (Biocolor, UK). Control: Undifferentiated con-
trol; Chondro Diff: Chondrogenic Differentiation. Results Presented as Mean ± SEM.
(DOCX)
S12 Table. Statistical significance differences in sulfated GAGs production (μg/ml) after
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control; D: Chondrogenic Differentiation. Significance of the results is indicated according to
P values with one, two, three or four of the symbols (�) corresponding to 0.01�P<0.05;
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